Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P F Redfern

Showing results (21-30 of 51) with videos related to

Pageof 6
Sort By:
Biochemical Pharmacology|February 14, 2002
Influence of isomerisation on the growth inhibitory effects and cellular activity of 13-cis and all-trans retinoic acid in neuroblastoma cellsGareth J Veal, Julie Errington, Christopher P F Redfern, et al.
Cell Calcium|August 13, 2005
Release and sequestration of Ca2+ by a caffeine- and ryanodine-sensitive store in a sub-population of human SH-SY5Y neuroblastoma cellsFiona C Riddoch, Sophie E Rowbotham, Anna M Brown, et al.
Experimental Dermatology|October 15, 2013
Oncogenic BRAF signalling increases Mcl-1 expression in cutaneous metastatic melanomaChristopher S McKee, David S Hill, Christopher P F Redfern, et al.
Molecular Pharmacology|December 4, 2003
Growth and DNA damage-inducible transcription factor 153 mediates apoptosis in response to fenretinide but not synergy between fenretinide and chemotherapeutic drugs in neuroblastomaMarco Corazzari, Penny E Lovat, Serafina Oliverio, et al.
Clinical Science (London, England : 1979)|March 1, 2002
Skeletal muscle mRNA levels for cathepsin B, but not components of the ubiquitin-proteasome pathway, are increased in patients with lung cancer referred for thoracotomyR Thomas Jagoe, Christopher P F Redfern, Russell G Roberts, et al.
Biochemical and Biophysical Research Communications|May 4, 2005
Fenretinide: a p53-independent way to kill cancer cellsMarco Corazzari, Penny E Lovat, Serafina Oliverio, et al.
Bioorganic & Medicinal Chemistry|August 30, 2008
Novel azolyl-(phenylmethyl)]aryl/heteroarylamines: potent CYP26 inhibitors and enhancers of all-trans retinoic acid activity in neuroblastoma cellsMohamed Sayed Gomaa, Jane L Armstrong, Beatrice Bobillon, et al.
Molecular Pharmacology|June 18, 2002
The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugsSally A Coulthard, Linda A Hogarth, Margaret Little, et al.
Journal of Medicinal Chemistry|August 16, 2011
Synthesis and biological evaluation of 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-[4-(naphthalen-2-ylamino)phenyl]propyl derivatives as small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26)Mohamed S Gomaa, Caroline E Bridgens, Gareth J Veal, et al.
Cell Cycle (Georgetown, Tex.)|November 5, 2011
Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expressionJane Carr-Wilkinson, Rebecca Griffiths, Rebecca Elston, et al.
Pageof 6

Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
Biochemical Pharmacology|February 14, 2002
Influence of isomerisation on the growth inhibitory effects and cellular activity of 13-cis and all-trans retinoic acid in neuroblastoma cellsGareth J Veal, Julie Errington, Christopher P F Redfern, et al.
Cell Calcium|August 13, 2005
Release and sequestration of Ca2+ by a caffeine- and ryanodine-sensitive store in a sub-population of human SH-SY5Y neuroblastoma cellsFiona C Riddoch, Sophie E Rowbotham, Anna M Brown, et al.
Experimental Dermatology|October 15, 2013
Oncogenic BRAF signalling increases Mcl-1 expression in cutaneous metastatic melanomaChristopher S McKee, David S Hill, Christopher P F Redfern, et al.
Molecular Pharmacology|December 4, 2003
Growth and DNA damage-inducible transcription factor 153 mediates apoptosis in response to fenretinide but not synergy between fenretinide and chemotherapeutic drugs in neuroblastomaMarco Corazzari, Penny E Lovat, Serafina Oliverio, et al.
Clinical Science (London, England : 1979)|March 1, 2002
Skeletal muscle mRNA levels for cathepsin B, but not components of the ubiquitin-proteasome pathway, are increased in patients with lung cancer referred for thoracotomyR Thomas Jagoe, Christopher P F Redfern, Russell G Roberts, et al.
Biochemical and Biophysical Research Communications|May 4, 2005
Fenretinide: a p53-independent way to kill cancer cellsMarco Corazzari, Penny E Lovat, Serafina Oliverio, et al.
Bioorganic & Medicinal Chemistry|August 30, 2008
Novel azolyl-(phenylmethyl)]aryl/heteroarylamines: potent CYP26 inhibitors and enhancers of all-trans retinoic acid activity in neuroblastoma cellsMohamed Sayed Gomaa, Jane L Armstrong, Beatrice Bobillon, et al.
Molecular Pharmacology|June 18, 2002
The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugsSally A Coulthard, Linda A Hogarth, Margaret Little, et al.
Journal of Medicinal Chemistry|August 16, 2011
Synthesis and biological evaluation of 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-[4-(naphthalen-2-ylamino)phenyl]propyl derivatives as small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26)Mohamed S Gomaa, Caroline E Bridgens, Gareth J Veal, et al.
Cell Cycle (Georgetown, Tex.)|November 5, 2011
Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expressionJane Carr-Wilkinson, Rebecca Griffiths, Rebecca Elston, et al.
Pageof 6